- Home
- ROIV
as 07-26-2024 4:00pm EST
Roivant Sciences Ltd is a commercial-stage biopharmaceutical company dedicated to improving the delivery of healthcare to patients. It also incubates discovery-stage companies and health technology startups complementary to its biopharmaceutical business. Its drug candidate VTAMA (tapinarof) is a treatment of plaque psoriasis in adult patients and is in its commercial stage. The other drug candidates in their different stages of development are; Batoclimab, IMVT-1402, Brepocitinib, Namilumab, and others.
| Founded: | 2014 | Country: | United Kingdom |
| Employees: | N/A | City: | HAMILTON HM11 |
| Market Cap: | 7.9B | IPO Year: | N/A |
| Target Price: | $17.33 | AVG Volume (30 days): | 4.8M |
| Analyst Decision: | Strong Buy | Number of Analysts: | 10 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 5.23 | EPS Growth: | N/A |
| 52 Week Low/High: | $8.25 - $13.24 | Next Earning Date: | 08-08-2024 |
| Revenue: | $124,795,000 | Revenue Growth: | 103.65% |
| Revenue Growth (this year): | 39.42% | Revenue Growth (next year): | 63.25% |
Stock Insider Trading Activity of Roivant Sciences Ltd. (ROIV)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Venker Eric | ROIV | President & COO | Feb 9 '24 | Sell | $10.92 | 96,950 | $1,058,694.00 | 532,207 | SEC Form 4 |
| Ramaswamy Vivek | ROIV | 10% Owner | Jan 2 '24 | Sell | $11.05 | 3,000,000 | $33,150,000.00 | 51,929,426 | SEC Form 4 |
Latest Roivant Sciences Ltd. News
ROIV Breaking Stock News: Dive into ROIV Ticker-Specific Updates for Smart Investing
GlobeNewswire
a day ago
Roivant to Report Financial Results for the First Quarter Ended June 30, 2024, and Provide Business Update on Thursday, August 8, 2024
GOBankingRates
2 months ago
5 Reasons a Biden Second Term Could Be a Financial Disaster for Boomers
Business Insider
2 months ago
US solar producers could finally have a fighting chance as tariffs kick in on cheaper imports from Asia
Insider Monkey
2 months ago
The Best Woody Perfume For Women
Reuters
2 months ago
Microsoft unveils all-digital Xbox consoles, 'Doom' title at Games Showcase
Insider Monkey
2 months ago
Best Date Night Fragrance in 2024
AFP
2 months ago
France's Macron calls snap legislative elections after EU poll blow
Investor's Business Daily
2 months ago
Dow Jones Futures Due; Apple AI Push, Fed Rate Outlook Lead 8 Big Market Events
Compare ROIV vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "ROIV Roivant Sciences Ltd. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.